Making Strides in the Treatment of B-Cell Malignancies

Making Strides in the Treatment of B-Cell Malignancies

A Case-Based Educational Activity

Not a member of My prIME? Join now for instant access.

Meeting Overview

Explore the options for the treatment of B-cell malignancies at prIME Oncology’s official satellite symposium at the annual hematology meeting in San Diego, California. Attendees will have the opportunity to engage with expert faculty speakers on the treatment of B-cell malignancies, including CLL, indolent non-Hodgkin lymphoma, aggressive lymphoma, mantle cell lymphoma, and more!

Please note that due to congress restrictions, spots are limited, and seats will be given on a first-come, first-serve basis. Please arrive by 7.15 AM to guarantee your spot.

Friday satellite symposium on Making Strides in the Treatment of B-Cell Malignancies, preceding the 60th ASH Annual Meeting and Exposition.

Date and Location

Friday, November 30, 2018
7.00 AM – 7.30 AM – Breakfast and Registration
7.30 AM – 11.00 AM – Educational Session

Grand Ballrooms 8-9
Marriott Marquis San Diego Marina
333 W Harbor Dr
San Diego, California 92101



Friday, November 30, 2018
7.00 AM – 11.00 AM



San Diego, California, United States



3.25 AMA PRA Category 1 Credit(s)™

7.00 AM Registration and breakfast
7.30 AM Welcome and introduction
Richard I. Fisher, MD
7.35 AM Starting warm up: “Hematology Guru” audience quiz
Richard I. Fisher, MD
7.40 AM A look at the hurdles associated with B-cell malignancies
Richard I. Fisher, MD
7.55 AM Interactive case in mantle cell lymphoma (MCL)
Simon Rule, MPhil, FRCP, FRCPA, FRCPath
8.00 AM MCL: Going the distance with emerging treatment options
Simon Rule, MPhil, FRCP, FRCPA, FRCPath
8.25 AM Q & A
8.30 AM Interactive case in chronic lymphocytic leukemia (CLL)
Jacqueline Barrientos, MD, MS
8.35 AM Treatment of CLL: It’s a marathon, not a sprint
Jacqueline Barrientos, MD, MS
9.00 AM Q & A
9.05 AM Break
9.20 AM Interactive case in follicular lymphoma (FL)
Nina Wagner-Johnston, MD
9.25 AM Keeping pace with treatment advances for FL
Nina Wagner-Johnston, MD
9.50 AM Q & A
9.55 AM Interactive case in diffuse large B-cell lymphoma (DBLCL)
John Seymour, MBBS, PhD, FRACP
10.00 AM DBLCL: Mapping out a course for individualized treatment
John Seymour, MBBS, PhD, FRACP
10.25 AM Q & A
10.30 AM Keeping eyes on the road ahead: An interactive panel discussion on future directions in B-cell malignancies
Faculty panel discussion/audience participation
10.45 AM “Hematology Guru” and prIME Points™
Richard I. Fisher, MD
11.00 AM Adjourn


  • Richard I. Fisher, MDFox Chase Cancer Center
    Philadelphia, Pennsylvania, United States
  • Faculty

  • Jacqueline C. Barrientos, MD, MSZucker School of Medicine at Hofstra/Northwell
    Lake Success, New York, United States
  • Simon Rule, MPhil, FRCP, FRCPA, FRCPathUniversity of Plymouth
    Plymouth, United Kingdom
  • John Seymour, MBBS, PhD, FRACPPeter MacCallum Cancer Centre
    Melbourne, Victoria, Australia
  • Nina Wagner-Johnston, MDJohns Hopkins Medicine
    Baltimore, Maryland, United States

This educational program is designed for hematologists, medical oncologists, and other healthcare professionals involved in the treatment of B-cell malignancies.

After successful completion of this educational activity, participants should be able to:

  • Evaluate the underlying biology of B-cell malignancies and emerging therapeutic targets
  • Analyze recent clinical trial data supporting the efficacy and safety of current and emerging therapies for the treatment of patients with B-cell malignancies
  • Employ best practices in treatment selection and sequencing based on patient and disease-related factors
  • Identify optimal strategies for addressing treatment-related adverse events and improving patient safety and quality of life

This educational activity is supported by grants from AbbVie Inc.; Celgene Corporation; and Merck and Co, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Emily Simpson prior to the live event at 678.686.7762.

There is no fee for this activity.


Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.